|
rTMS-stroke-phase I |
2009-05-29 |
CIREN |
|
Nimotuzumab in tumors of head and neck .Phase IV |
2013-02-01 |
CIMAB |
|
Effectiveness and safety of ior®EPOCIM in Chronic Kidney Disease patients in pre-dialysis. |
2011-11-11 |
CIMAB |
|
h-R3 MaB and radiotherapy in pediatric patients with intrinsic diffuse astrocytomas of brain stem, phase II. |
2010-12-28 |
CIM |
|
NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II. |
2010-12-29 |
CIM |
|
hR3 MAb in combination with chemo-embolization in hepatocellular carcinoma. |
2010-12-29 |
CIM |
|
hR3 monoclonal antibody combined with chemoembolization in mestatatic liver treatment. |
2010-12-29 |
CIM |
|
99mTc-marked 14F7 MaB in metastatic breast, phase II |
2008-12-27 |
CIM |
|
99mtc-marked 14f7 MAb in colon/rectum tumor, Phase II |
2010-12-17 |
CIM |
|
NGcGM3/VSSP/Montanide ISA 51 vaccine for breast cancer IIa, IIb and IIIa surgically treated with positive ganglia and disease-free, Phase IIb/III. |
2010-12-17 |
CIM |
|
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab |
12/05/2020 |
CIM |
|
NGcGM3/VSSP in small cell lung cancer |
07/12/2016 |
CIM |
|
NGcGM3/VSSP in Metastatic melanoma |
07/12/2016 |
CIM |
|
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma |
05/11/2013 |
CIM |
|
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. |
23/05/2014 |
CIM |
|
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. |
26/05/2014 |
CIM |
|
Predictor of response with CIMAvax EGF© in NSCLC Phase III |
29/01/2016 |
CIM |
|
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus |
23/12/2016 |
CIM |
|
1B8 vs MabThera® in patients with Diffuse large B-cell lymphoma |
01/09/2016 |
CIM |
|
Nimotuzumab-pancreatic cancer-adults-Phase IV. |
30/04/2017 |
CIM |
